title: Genipin inhibits mitochondrial uncoupling protein 2 expression and ameliorates podocyte injury in diabetic mice.
abstract: Diabetic nephropathy (DN) is one of the most common causes of end stage renal disease (ESRD) in China, which requires renal replacement therapy. Recent investigations have suggested an essential role of podocyte injury in the initial stage of DN. This study investigated the potential therapeutic role of genipin, an active extract from a traditional Chinese medicine, on progression of DN in diabetic mice induced by intraperitoneally injection of streptozocin (STZ). In diabetic mice, orally administration of genipin postponed the progression of DN, as demonstrated by ameliorating body weight loss and urine albumin leakage, attenuating glomerular basement membrane thickness, restoring the podocyte expression of podocin and WT1 in diabetic mice. The protective role of genipin on DN is probably through suppressing the up-regulation of mitochondrial uncoupling protein 2 (UCP2) in diabetic kidneys. Meanwhile, through inhibiting the up-regulation of UCP2, genipin restores podocin and WT1 expression in cultured podocytes and attenuates glucose-induced albumin leakage through podocytes monolayer. Therefore, these results revealed that genipin inhibited UCP2 expression and ameliorated podocyte injury in DN mice.
authors: Center for Kidney Disease, 2nd Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
authors: Wenjing
authors: W
authors: Qiu
authors: Yang
authors: Y
authors: Zhou
authors: Lei
authors: L
authors: Jiang
authors: Li
authors: L
authors: Fang
authors: Lu
authors: L
authors: Chen
authors: Weifang
authors: W
authors: Su
authors: Ruoyun
authors: R
authors: Tan
authors: Chen-yu
authors: CY
authors: Zhang
authors: Xiao
authors: X
authors: Han
authors: Junwei
authors: J
authors: Yang
mesh_terms: D000284:Administration, Oral; D000419:Albuminuria / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D000818:Animals; D002756:Cholagogues and Choleretics / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D010450:Endopeptidases / Q000096:biosynthesis*; D005786:Gene Expression Regulation / Q000187:drug effects*; D039823:Iridoids / Q000494:pharmacology*; D008297:Male; D008516:Medicine, Chinese Traditional; D051379:Mice; D050199:Podocytes / Q000378:metabolism* / Q000473:pathology; D064570:Ubiquitin-Specific Proteases
chemical_list: D002756:Cholagogues and Choleretics; D039823:Iridoids; C007834:genipin; D010450:Endopeptidases; D064570:Ubiquitin-Specific Proteases